Home > Boards > US Listed > Medical - Equipment > Itamar Medical Ltd. (ITMR)

Itamar Medical Reports First Quarter 2020 Financial Results

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 128
Posts 26,162
Boards Moderated 4
Alias Born 02/07/04
160x600 placeholder
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 12/16/2021 4:11:41 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) Edgar (US Regulatory) - 12/16/2021 8:42:15 AM
Itamar Medical EPS beats by $0.23, beats on revenue Seeking Alpha - 11/18/2021 6:24:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/18/2021 6:04:28 AM
Itamar Medical Reports Third Quarter 2021 Financial Results GlobeNewswire Inc. - 11/18/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2021 4:06:47 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/14/2021 5:21:24 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/4/2021 6:05:02 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/13/2021 5:28:31 PM
ATER, AXTI and OIIM among mid-day movers Seeking Alpha - 9/13/2021 1:25:44 PM
Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a) Edgar (US Regulatory) - 8/12/2021 8:25:03 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:36:47 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:31:21 AM
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors GlobeNewswire Inc. - 8/12/2021 6:00:00 AM
Itamar Medical Reports Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/10/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 7/28/2021 6:08:19 AM
Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021 GlobeNewswire Inc. - 7/28/2021 6:00:00 AM
Teleflex and Itamar sell off “too draconian”: Piper Sandler Seeking Alpha - 7/16/2021 4:57:40 PM
Itamar Medical to Present at the Ladenburg Thalmann Annual Healthcare Conference on Wednesday, July 14, 2021 GlobeNewswire Inc. - 6/30/2021 6:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/17/2021 11:07:41 AM
Itamar Medical Launches Enhancements to WatchPAT™ Product Line at SLEEP 2021 GlobeNewswire Inc. - 6/7/2021 6:00:00 AM
Itamar Medical Appoints Brad Fluegel to its Board of Directors GlobeNewswire Inc. - 5/24/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/20/2021 6:09:20 AM
Itamar Medical EPADS beats by $0.01, beats on revenue Seeking Alpha - 5/19/2021 6:03:06 AM
Itamar Medical Reports First Quarter 2021 Results GlobeNewswire Inc. - 5/19/2021 6:00:00 AM
midastouch017   Wednesday, 05/27/20 06:25:54 AM
Re: None
Post # of 12 
Itamar Medical Reports First Quarter 2020 Financial Results

May 27, 2020 06:00 ET | Source: Itamar Medical Ltd.

- First Quarter 2020 Revenues Increase 38% to $8.4 Million -

- WatchPAT™ Revenues Increase 41% to $8.2 Million -

- Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT -

CAESAREA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices and solutions to aid in the diagnosis of respiratory sleep disorders, today reported unaudited financial results for the first quarter of 2020.

“Our first quarter results illustrate a strong start to the year, which has persisted into the second quarter. Despite largely COVID-19 driven weakness in sales of our WatchPAT multiuse test, we have seen a dramatic increase in sales of our WatchPAT ONE device — the only commercially available, fully disposable home sleep apnea test (HSAT) currently available on the market,” said Gilad Glick, President and Chief Executive Officer of Itamar Medical.

“This is a difficult time for our customers and the patients they treat, but we are hopeful that we can continue to play a large role in supporting the accelerated evolution to home based care using digital health platforms. Importantly, as the healthcare world likely moves to a more virtual-based environment and infection risk management stays a key priority, we see a tremendous opportunity to reach the estimated 26% of adults worldwide suffering from sleep apnea with our comprehensive sleep disorder diagnostic platform,” concluded Glick.

First Quarter 2020 Highlights

Revenues in the first quarter of 2020 were $8.4 million, an increase of 38% year-over-year.

U.S. WatchPAT revenues in the first quarter of 2020 were $6.1 million, an increase of 42% year-over-year.

Gross margin in the first quarter of 2020 was 76%, compared to 77% in the first quarter of 2019.

Completed a U.S. public offering in February 2020 with total gross proceeds of $40.3 million, ending the first quarter 2020 with $50.4 million in cash and cash equivalents.
Recent Business Developments and COVID-19 Updates

While the overall sleep testing market has contracted significantly due to the impact of the COVID-19 outbreak, Itamar Medical continued to gain significant momentum in the period from April 1, 2020 through May 22 , 2020, compared to the same period in the prior year. While the Company does not expect to offer mid-quarter financial updates going forward, this momentum was reflected in the following Key Performance Indicators (KPIs):

Grew total value of sales orders in the U.S. approximately 48% year-over-year, including a material order in connection with our contract with Lunella LLC, a wholly owned subsidiary of SoClean Inc. and their recent launch of our WatchPAT ONE through their DTC marketing channels. Excluding this order, year-over year growth was 23% for the same period, primarily driven by WatchPAT ONE orders.

Onboarded an average of 21 new WatchPAT ONE customers per week, reaching 210 active centers (mostly sleep centers) using WatchPAT ONE as of May 22, 2020.

Increased WatchPAT ONE backlog to approximately $850,000 as of May 22, 2020, compared to approximately $550,000 as of March 31, 2020 despite consistent increases in weekly units’ shipments.

Expanded WatchPAT ONE production output to approximately 3,000 units for the week ended May 22, 2020, representing an approximately 300% increase from the pre-COVID-19 baseline level.

Received CE mark approval in Europe for the WatchPAT ONE product.

Entered into an agreement with Sleep Data Diagnostic and its virtual-care platform BetterNight and Sleep Data Holdings to simplify the process by which both sleep and non-sleep referring physicians can refer patients for sleep apnea testing with WatchPAT through Itamar Medical and BetterNight’s platforms, providing a full care pathway.

Entered into an agreement to fund a clinical study conducted at Mount Sinai Hospital in New York City to evaluate the potential impact of CPAP therapy in both sleep apnea and non-sleep apnea patients in delaying or eliminating hospitalization and/or ventilation in patients suspected or diagnosed with COVID-19.
First Quarter 2020 Financial Results

Revenues for the first quarter of 2020 increased 38% to $8.4 million, compared to $6.1 million in the same quarter in 2019. Revenue growth was driven by an increase in WatchPAT sales in the U.S. and Japan.

WatchPAT revenues for the first quarter of 2020 increased 41% to $8.2 million, compared to $5.8 million in the same quarter in 2019.

U.S. WatchPAT revenues for the first quarter of 2020 increased 42% to $6.1 million, compared to $4.3 million in the same quarter in 2019. Sales from disposables and renewable products, including WatchPAT ONE, comprised approximately 75% of WatchPAT revenues in the U.S. in the first quarter of 2020, compared to 77% in the same quarter in 2019.

Gross profit for the first quarter of 2020 increased to $6.3 million, compared to $4.7 million in the same quarter in 2019. Gross profit margin for the first quarter of 2020 was approximately 76%, compared to 77% in the same quarter in 2019. Gross margin decline was mainly driven by the increase in WatchPAT ONE sales.

Operating loss for the first quarter of 2020 was $2.0 million, compared to $1.3 million in the same quarter in 2019. The increase in operating loss was mainly due to an increase of $1.5 million in selling and marketing expenses associated with the expansion of the U.S. sales team into new geographical territories and verticals (32 territories and verticals as of March 31, 2020, compared to 23 territories and verticals as of March 31, 2019) as well as additional sales commissions resulting from the increase in revenues; an increase of $0.4 million in research and development expenses associated with an increase in personnel to support product development and clinical study programs and reimbursement consulting; and an increase of $0.4 million in general and administrative expenses mainly attributable to expenses of a publicly listed company in the U.S., partially offset by the increase in revenues.

Non-IFRS operating loss for the first quarter of 2020 was $1.4 million, compared to $1.0 million in the same quarter in 2019. Non-IFRS operating loss excludes approximately $0.6 million in share-based payments; depreciation and amortization of property and equipment and intangible assets; and change in provision for doubtful and bad debt, compared to $0.3 million of similar expenses for the same quarter in 2019 (see “Use of Non-IFRS Measures” below).

Net loss for the first quarter of 2020 was $2.0 million, compared to $1.2 million in the same quarter in 2019.

Non-IFRS net loss for the first quarter of 2020 was $1.4 million, compared to $1.2 million in the same quarter in 2019. Non-IFRS net loss excludes approximately $0.6 million in share-based payments; depreciation and amortization of property and equipment and intangible assets; change in provision for doubtful and bad debt; and gain from reevaluation of derivatives, compared to ($0.1) million of similar expenses and gains for the same quarter in 2019 (see “Use of Non-IFRS Measures” below).

As of March 31, 2020, the Company had cash and cash equivalents of $50.4 million. This amount includes the net proceeds from the public offering completed in February 2020 of $37.1 million.

Conference Call and Webcast Information

The Company will host a conference call today at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update.

To listen live via webcast, please visit https://www.itamar-medical.com/, or by clicking here.

To participate via phone, please use the dial in information:

U.S. toll-free: 877-407-8037
International: 201-689-8037
Israel toll-free: 1-809-406-247

Please log in approximately 10 minutes prior to the scheduled start time. An archived webcast also will be provided in the Events and Presentations section of the Company’s website.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences